C4 Therapeutics, Inc.

AI-generated fair value estimate for this company.

Method: Sum-of-the-parts biotech valuation: net cash & equivalents of $300.4M (Q2 2026, per company report) / 123.03M shares outstanding = $2.44/share cash value, plus risk-adjusted pipeline/collaboration optionality valued at 3x the annualized Roche collaboration revenue run-rate ($6.6M quarterly x 4 = $26.4M annualized x 3 = $79.2M / 123.03M shares = $0.64/share); total intrinsic value ≈ $2.44 + $0.64 = $3.08/share.

Reasoning: C4 Therapeutics is a clinical-stage biotech with a Roche partnership and cash runway guided to 2028; cash-plus-risk-adjusted-pipeline-optionality is the standard approach for pre-profit biotechs instead of a DCF built on currently negative free cash flow.